Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 6Phase NA 4Phase EARLY_PHASE1 3Phase 3 3Phase 1/2 3

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Carcinoma, Non-Small-Cell Lung 146Breast Neoplasms 111Prostatic Neoplasms 59Neoplasms 54Multiple Myeloma 54Lung Neoplasms 49Neoplasm Metastasis 40Ovarian Neoplasms 33Colorectal Neoplasms 32Parkinson Disease 4, Autosomal Dominant Lewy Body 31Leukemia, Lymphocytic, Chronic, B-Cell 31Recurrence 26Leukemia, Myeloid, Acute 26Carcinoma, Renal Cell 25Urinary Bladder Neoplasms 23Triple Negative Breast Neoplasms 21Small Cell Lung Carcinoma 21Myasthenia Gravis 21Endometrial Neoplasms 21Carcinoma, Hepatocellular 21Lymphoma, Large B-Cell, Diffuse 20Squamous Cell Carcinoma of Head and Neck 19Melanoma 18Lymphoma, Follicular 18Nasopharyngeal Carcinoma 17Fallopian Tube Neoplasms 16Pancreatic Neoplasms 15Non-Muscle Invasive Bladder Neoplasms 15Brain Neoplasms 15Stomach Neoplasms 14

Interventions

Lenalidomide 2Bortezomib 2pomalidomide 1elotuzumab 1carfilzomib 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms, Plasma Cell × 90 days × Clear all
NCT06152575 2026-06-05

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Pfizer

Phase 3 Recruiting
492 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00430365 2026-04-06

IFM2005-02

University Hospital, Toulouse

Phase 3 Completed
614 enrolled
Plasma cell

Neoplasms, Plasma Cell

NCT01191060 2026-04-06

IFM/DFCI2009

University Hospital, Toulouse

Phase 3 Completed
700 enrolled
Plasma cell

Disease Progression, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡